FDA extends Agios' mitapivat sickle cell sNDA PDUFA date to February 1, 2027 after major amendment

 

• Previous PDUFA goal date for mitapivat in sickle cell disease was November 1, 2026.
• FDA classified additional mitapivat sickle cell disease safety data as a major amendment to the sNDA.

https://finviz.com/stock?t=AGIO&p=d